Immix Biopharma (IMMX) Stock Price, News & Analysis

Company Overview

Immix Biopharma, Inc. is a clinical‐stage biotechnology company developing a proprietary class of polymer‐conjugate therapeutics designed to improve the delivery and efficacy of anti‐cancer agents. The company’s platform leverages water‐soluble polymer backbones that can be selectively loaded with cytotoxic drugs, enabling enhanced tumor targeting, controlled drug release and reduced systemic toxicity. Immix’s lead candidate, IMX‐110, combines a potent chemotherapy payload with polymer technology to address treatment‐resistant solid tumors and hematologic malignancies, with ongoing studies in ovarian cancer, pancreatic cancer and acute myeloid leukemia.

In addition to IMX‐110, Immix Biopharma is advancing a second program, IMX‐017, which utilizes the same polymer conjugation approach to deliver novel chemotherapeutic agents. Preclinical data indicate that polymer conjugation enhances the pharmacokinetic profile of small‐molecule drugs, prolonging circulation time and improving penetration of tumor tissue. The company’s development strategy includes both stand‐alone administration and combination regimens to maximize therapeutic benefit while limiting off‐target effects.

Founded in 2013 and headquartered in San Antonio, Texas, Immix Biopharma conducts its research and development activities across key U.S. and European oncology centers. The company’s robust preclinical and clinical collaborations with academic institutions and contract research organizations support its efforts to advance pipeline candidates through regulatory milestones. Immix is committed to expanding its geographic reach, with plans to initiate multi‐site clinical trials in North America and select European markets.

Immix Biopharma is led by a management team and board of directors with extensive experience in oncology drug development, clinical operations and regulatory affairs. The leadership group includes veterans from leading pharmaceutical and biotechnology firms, ensuring strategic guidance in advancing Immix’s innovative polymer‐conjugate platform from early‐stage research to late‐stage clinical evaluation.

Key Stats

• Today's Range: $2.61 to $2.74
• 50-Day Range: $1.95 to $2.75
• 52-Week Range: $1.26 to $3.00
• Volume: 286,916 shs
• Average Volume: 151,193 shs
• Market Capitalization: $73.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Buy

Immix Biopharma Stock Analysis - MarketRank™

Immix Biopharma scored higher than 71% of companies evaluated by MarketBeat, and ranked 303rd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Immix Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Immix Biopharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Immix Biopharma are expected to grow in the coming year, from ($0.87) to ($0.85) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Immix Biopharma is -3.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Immix Biopharma is -3.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Immix Biopharma has a P/B Ratio of 5.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.00% of the float of Immix Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Immix Biopharma has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Immix Biopharma has recently decreased by 32.56%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Immix Biopharma does not currently pay a dividend.

Dividend Growth

Immix Biopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.00% of the float of Immix Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Immix Biopharma has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Immix Biopharma has recently decreased by 32.56%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.59

News Sentiment

Immix Biopharma has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.01 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Immix Biopharma this week, compared to 1 article on an average week.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Immix Biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,061.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

55.40% of the stock of Immix Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 11.26% of the stock of Immix Biopharma is held by institutions.

IMMX Stock Analysis - Frequently Asked Questions

How have IMMX shares performed this year?

Immix Biopharma's stock was trading at $2.20 at the beginning of 2025. Since then, IMMX stock has increased by 20.5% and is now trading at $2.65.

How were Immix Biopharma's earnings last quarter?

Immix Biopharma, Inc. (NASDAQ:IMMX) posted its earnings results on Monday, March, 24th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.09.

When did Immix Biopharma IPO?

Immix Biopharma (IMMX) raised $23 million in an IPO on Thursday, December 16th 2021. The company issued 4,200,000 shares at a price of $5.00-$6.00 per share.

How do I buy shares of Immix Biopharma?

Shares of IMMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Immix Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Immix Biopharma investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), Disc Medicine (IRON), e.l.f. Beauty (ELF) and Adobe (ADBE).

Company Calendar

• Last Earnings: 3/24/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IMMX
• CIK: 1873835
• Web: www.immixbio.com
• Phone: 310-651-8041
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Immix Biopharma: $7.00
• High Price Target: $7.00
• Low Price Target: $7.00
• Potential Upside/Downside: +164.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.61 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -130.02%
• Return on Assets: -86.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.80
• Quick Ratio: 1.80

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.48 per share
• Price / Book: 5.52

Miscellaneous

• Outstanding Shares: 27,880,000
• Free Float: 12,433,000
• Market Cap: $73.88 million
• Optionable: Optionable
• Beta: 0.24